Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafolecimab Combined With Sintilimab and CapeOX as Neoadjuvant Treatment for Locally Advanced Colon Cancer
NCT07840677Phase 2Recruiting
- Start
- Sep 2026
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tafolecimab in colon cancer (2 arms). Primary endpoint: Pathological Complete Response at 12 weeks. Started Sep 2026; status: recruiting.
02
Drugs
tafolecimab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT07840677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07840677.